Eyevensys adds Drs Neena Kadaba and Dominik Escher to Board along with raising $30m Series B financing led by Boehringer Ingelheim Venture Fund
– FRANCE, Paris – Eyevensys, a privately held clinical-stage biotechnology company developing non-viral gene therapies for retinal and other ophthalmic diseases, today announced that it has completed a $30 million Series B financing led by Boehringer Ingelheim Venture Fund and included participation from existing investors Pontifax, Bpifrance, CapDecisif, and Inserm Transfert, as well as new investors, the Global Health Sciences Fund and Pureos Bioventures.…